Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC

Exploring Treatment Advancements in aRCC with CTLA-4 and PD-1 Inhibition

Date

14 Sep 2020

Session

Bristol Myers Squibb - Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRCC

Presenters

Nizar Tannir

Authors

N. Tannir

Author affiliations

  • Genitourinary Medical Oncology, The M. D. Anderson Cancer Center, 77030 - Houston/US
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings